ArticleAmerican journal of cancer research2021

A phase 1, multicenter study evaluating the safety and efficacy of KITE-585, an autologous anti-BCMA CAR T-cell therapy, in patients with relapsed/refractory multiple myeloma.

Robert F Cornell et al.PubMed ↗Full text ↗

No numbers read from the abstract.